A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

George R. Blumenschein, E. F. Smit, D. Planchard, D. W. Kim, J. Cadranel, T. De Pas, F. Dunphy, K. Udud, M. J. Ahn, N. H. Hanna, J. H. Kim, J. Mazieres, S. W. Kim, P. Baas, E. Rappold, S. Redhu, A. Puski, F. S. Wu, P. A. Jänne

Research output: Contribution to journal › Article › peer-review

260 Scopus citations

Fingerprint

Dive into the research topics of 'A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)'. Together they form a unique fingerprint.

Medicine & Life Sciences